Pharmacogenetics place in modern medical science and practice.
Pharmacogenetic evidence-based treatment strategies will have major implications for all aspects of the product pipeline, including drug discovery, high throughput target screening protocols, lead optimization, and drug formulation to produce series of medicines for a particular disease which will meet the efficacy needs of the majority of patients. The initial proof of principle experiments involves whole genome screening for DNA variants and determination of specific patterns of variants associated with adverse events of marketed products [SNP Print(sm)]. Pharmacogenetics has the potential of changing the pipeline model of drug discovery, clinical development, and mass customization marketing.
Roses
Allen D
AD
Genetics Research, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. adr69412@gsk.com
D004358:Drug Therapy; D019317:Evidence-Based Medicine / Q000379:methods*; D015894:Genome, Human; D016045:Human Genome Project; D006801:Humans; D004364:Pharmaceutical Preparations; D010597:Pharmacogenetics / Q000639:trends*
D004364:Pharmaceutical Preparations